Search Results
Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer
APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancer
SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer Institute
5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC
Key data from the San Antonio Breast Cancer Symposium (SABCS) 2022
Patient Perspectives on T-DM1 vs Paclitaxel/Trastuzumab for HER2+ Early Breast Cancer
Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer
Adjuvant treatment for stage I HER2+ breast cancer
Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer
HER-RAM: investigating trastuzumab, ramucirumab and paclitaxel for the second-line treatment of GC
Sacituzumab govitecan effective for HR+ metastatic breast cancer regardless of Trop-2 status
